BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25648497)

  • 1. Potentiating effects of GHRH analogs on the response to chemotherapy.
    Schally AV; Perez R; Block NL; Rick FG
    Cell Cycle; 2015; 14(5):699-704. PubMed ID: 25648497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel.
    Hohla F; Schally AV; Szepeshazi K; Varga JL; Buchholz S; Köster F; Heinrich E; Halmos G; Rick FG; Kannadka C; Datz C; Kanashiro CA
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14513-8. PubMed ID: 16983095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers.
    Perez R; Schally AV; Vidaurre I; Rincon R; Block NL; Rick FG
    Oncotarget; 2012 Sep; 3(9):988-97. PubMed ID: 22941871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
    Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
    Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer.
    Schally AV; Varga JL; Engel JB
    Nat Clin Pract Endocrinol Metab; 2008 Jan; 4(1):33-43. PubMed ID: 18084344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone.
    Wang H; Zhang X; Vidaurre I; Cai R; Sha W; Schally AV
    Int J Cancer; 2018 Jun; 142(11):2394-2404. PubMed ID: 29435973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical study.
    Perez R; Schally AV; Popovics P; Cai R; Sha W; Rincon R; Rick FG
    Oncoscience; 2014; 1(10):665-73. PubMed ID: 25593995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH.
    Schally AV; Wang H; He J; Cai R; Sha W; Popovics P; Perez R; Vidaurre I; Zhang X
    Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12028-12033. PubMed ID: 30373845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.
    Szalontay L; Schally AV; Popovics P; Vidaurre I; Krishan A; Zarandi M; Cai RZ; Klukovits A; Block NL; Rick FG
    Cell Cycle; 2014; 13(17):2790-7. PubMed ID: 25486366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
    Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
    Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity.
    Cai R; Zhang X; Wang H; Cui T; Halmos G; Sha W; He J; Popovics P; Vidaurre I; Zhang C; Mirsaeidi M; Schally AV
    Peptides; 2022 Apr; 150():170716. PubMed ID: 34952135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.
    Buchholz S; Schally AV; Engel JB; Hohla F; Heinrich E; Koester F; Varga JL; Halmos G
    Proc Natl Acad Sci U S A; 2007 Feb; 104(6):1943-6. PubMed ID: 17261802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer.
    Rick FG; Seitz S; Schally AV; Szalontay L; Krishan A; Datz C; Stadlmayr A; Buchholz S; Block NL; Hohla F
    Cell Cycle; 2012 Nov; 11(22):4203-10. PubMed ID: 23095641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition.
    Köster F; Engel JB; Schally AV; Hönig A; Schröer A; Seitz S; Hohla F; Ortmann O; Diedrich K; Buchholz S
    Breast Cancer Res Treat; 2009 Jul; 116(2):273-9. PubMed ID: 18629632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
    Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
    Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
    Papadia A; Schally AV; Halmos G; Varga JL; Seitz S; Buchholz S; Rick F; Zarandi M; Bellyei S; Treszl A; Szalontay L; Lucci JA
    Horm Metab Res; 2011 Oct; 43(11):816-20. PubMed ID: 22009378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth.
    Zarandi M; Cai R; Kovacs M; Popovics P; Szalontay L; Cui T; Sha W; Jaszberenyi M; Varga J; Zhang X; Block NL; Rick FG; Halmos G; Schally AV
    Peptides; 2017 Mar; 89():60-70. PubMed ID: 28130121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
    Chatzistamou I; Schally AV; Varga JL; Groot K; Armatis P; Busto R; Halmos G
    J Clin Endocrinol Metab; 2001 May; 86(5):2144-52. PubMed ID: 11344219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
    Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
    Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.